(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.07%) $0.927
(0.30%) $10.87
(0.07%) $0.793
(-0.32%) $92.28
Live Chart Being Loaded With Signals
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases...
Stats | |
---|---|
Today's Volume | 259.00 |
Average Volume | 10 769.00 |
Market Cap | 62.78M |
EPS | SEK0 ( 2023-10-31 ) |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.520 |
ATR14 | SEK0 (0.00%) |
Lipum AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lipum AB (publ) Financials
Annual | 2022 |
Revenue: | SEK0 |
Gross Profit: | SEK-11 000.00 (0.00 %) |
EPS: | SEK-6.02 |
Q3 | 2023 |
Revenue: | SEK115 000 |
Gross Profit: | SEK102 000 (88.70 %) |
EPS: | SEK-0.710 |
Q2 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK0 (0.00 %) |
EPS: | SEK-1.820 |
Q1 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-3 000.00 (0.00 %) |
EPS: | SEK-0.940 |
Financial Reports:
No articles found.
Lipum AB (publ)
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators